- Home
- TPST vs AEON Comparison
TPST vs AEON Comparison
Compare TPST & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | AEON |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 26.8M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | TPST | AEON |
|---|---|---|
| Price | $2.36 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $11.00 | $7.20 |
| AVG Volume (30 Days) | ★ 267.3K | 125.6K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $295,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.50 | $0.38 |
| 52 Week High | $12.22 | $1.45 |
Technical Indicators
Market Signals| Indicator | TPST | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 48.60 |
| Support Level | $2.14 | $0.69 |
| Resistance Level | $2.49 | $1.12 |
| Average True Range (ATR) | 0.19 | 0.11 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 88.54 | 30.34 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.